KYTX vs LXEO: fair value comparison
Kyverna Therapeutics, Inc. and Lexeo Therapeutics, Inc. · Updated 2026-10-19
KYTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. LXEO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, KYTX currently ranks higher by quality score.
| KYTX | LXEO | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $5.67 | $2.64 |
| 12-month range | $5.67–$11.25 | $2.63–$10.63 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #246 of 301 Healthcare | #248 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: KYTX fair value analysis · LXEO fair value analysis